Extended Range of Process-Scale Columns Prepacked with CEX, AEX, CEX-HIC, and AEX-HIC Chromatography Resins Provides an Effective Solution for Purification of Biomolecules in Downstream Processing

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of prepacked process-scale Foresight™ Pro chromatography columns packed with Bio-Rad’s scalable Nuvia™ chromatography resins, for downstream process-scale chromatography applications throughout the various stages in biological drug development and manufacturing.

The extended range includes columns packed with anion exchangers (AEX) Nuvia Q Media and Nuvia HP-Q Media, cation exchanger (CEX) Nuvia HR-S Media, and mixed-mode (MM) resins Nuvia cPrime Media, a CEX-hydrophobic interaction chromatography (CEX-HIC) resin, and Nuvia aPrime 4A Media, an AEX-HIC chromatography resin. These options expand the existing family of Foresight Pro columns packed with CHT™ Ceramic Hydroxyapatite Media Type I, Type II, and XT, which have been incorporated into various regulatory-approved processes worldwide. Columns prepacked with Nuvia resins are now available with internal diameters (ID) of 5 to 13 cm and bed heights of 10 and 20 cm. Columns with IDs of 20 to 45 cm are also in development with anticipated availability in early 2027.

Nuvia chromatography resins use Bio-Rad’s Nuvia bead technology, featuring a polyacrylamide (acrylamide polymer) base bead suitable for laboratory-scale purification, process development, pilot-scale production, and commercial biomanufacturing applications. Bio-Rad’s Nuvia resins are designed to have minimal non-specific binding reactions, due to the hydrophilic nature of the bead polymer, and maintain a constant dynamic binding capacity over a wide range of flow rates. The Nuvia bead allows for fast mass transfer and is chemically and mechanically stable over a wide range of conditions. All Bio-Rad Foresight Pro Columns are manufactured in a controlled ISO Class 7 cleanroom, providing good manufacturing practice (GMP) ready columns. The prepacked columns’ standardized design and format can provide a more cost-effective and flexible solution than customer-packed columns, and columns are available in a range of diameters and bed volumes.

“The new Nuvia prepacked Foresight Pro chromatography columns build on the strong market response to our original CHT Ceramic Hydroxyapatite Media columns, which launched in 2022,” said Diab Elmashni, Director, Process Chromatography Business at Bio-Rad Laboratories. “Customers asked us for column options built around different resins, and this line is our response. What sets these columns apart is that each one is packed using media from a single production lot, instead of blending multiple resin batches together during packing. That single-lot approach is what makes our Foresight Pro Columns a genuinely unique, single-source offering, providing biopharma customers with superior technical, application, and product support.”

Visit bio-rad.com/ForesightProColumns for more information.

BIO-RAD, NUVIA, CHT, and FORESIGHT are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

The Foresight Pro Column hardware design is covered by U.S. Patent Number 11,841,350 and foreign counterparts. Nuvia aPrime 4A Media is covered by U.S. Patent Numbers 9,669,402 and 10,682,640, and foreign counterparts. Nuvia cPrime Media is covered by U.S. Patent Numbers 9,309,282, 10,792,654, and 11,590,486, and foreign counterparts.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,400 employees and $2.6 billion in revenues in 2025. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.